Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.